Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi(Harvard University), David E. Fisher(Massachusetts General Hospital), Kevin B. Kim(The University of Texas MD Anderson Cancer Center), Keith T. Flaherty(Cancer Research Center), Philip Friedlander(Institute for Tourism), Christopher L. Corless(Oregon Health & Science University), Jeffrey T. Yap(Institute for Tourism), Adrián Mariño‐Enríquez(Harvard University Press), Jonathan A. Fletcher(Borders General Hospital), Katherine Zukotynski(Unknown), Jeffrey S. Weber(NYU Langone Health), Mei‐Jun Zhu(Washington State University), Donald P. Lawrence(Massachusetts General Hospital), Steven O’Day(Saint John's Health Center), George D. Demetri(Dana-Farber Cancer Institute), Carol Beadling(Oregon Health & Science University), Jason J. Luke(University of Chicago), Anita Giobbie‐Hurder(Institute for Tourism), Annick D. Van den Abbeele(Unknown), Thomas F. Gajewski(University of Chicago), Marc S. Ernstoff(National Cancer Institute), Frances A. Collichio(Institute for Tourism), Michael C. Heinrich(VA Portland Health Care System), René González(University of Miami)
Cited by 594
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k